Ajovy carries a wholesale list price of about $733 for a 30-day supply, which adds up to roughly $8,800 per year. That’s not unusual for its drug class, but it’s dramatically more than older migraine prevention medications like propranolol, which costs around $1,400 a year in generic form. Several factors stack on top of each other to keep the price this high.
Biologic Drugs Cost More to Make
Ajovy isn’t a traditional pill synthesized from chemical reactions. It’s a monoclonal antibody, a type of biologic drug grown inside living cells. That distinction matters enormously for cost. Manufacturing a monoclonal antibody requires specialized facilities with massive capital investment, highly controlled environments, and production cycles that are slower and less efficient than conventional drug manufacturing.
The process involves growing engineered cells in large bioreactors, feeding them precise nutrient schedules, and then extracting and purifying the antibody protein from everything else the cells produce. Purification alone is expensive because it relies on costly materials like protein A resin. Batch-to-batch consistency is difficult to maintain, and scaling up production introduces new challenges at every stage. Traditional batch processing causes nutrients to deplete and waste to accumulate, which can kill cells early and compromise the final product. More advanced feeding schedules help, but they add complexity and make scaling harder.
None of this resembles pressing a generic pill. Every step requires quality testing that small-molecule drugs simply don’t need, and any contamination can ruin an entire batch worth millions of dollars.
Research Investment Gets Built Into the Price
Bringing any new drug to market typically costs hundreds of millions to billions of dollars over a decade or more of research, and biologic drugs sit at the expensive end of that range. Ajovy’s manufacturer, Teva Pharmaceuticals, funded years of preclinical research followed by multiple phases of clinical trials involving thousands of migraine patients before the FDA approved the drug in 2018. Companies price branded drugs to recoup those costs during the window when they have exclusive market rights, which means the relatively small population of migraine patients who use Ajovy absorbs the full R&D investment through higher per-unit pricing.
Patent Protection Blocks Cheaper Alternatives
Ajovy’s core patents expire in 2027 in the United States and 2026 in Europe. But a separate patent covering its specific use in migraine treatment doesn’t expire until 2035. That layered patent strategy is common in the pharmaceutical industry and could delay biosimilar competitors (the biologic equivalent of generics) well beyond the initial patent expiration. Until biosimilars reach the market, there’s no lower-cost version of the same molecule to create downward price pressure.
Even when patents do expire, biosimilars face a harder path than generic pills. Because monoclonal antibodies are complex proteins made by living cells, a competitor can’t simply copy the chemical formula. They need to demonstrate through their own clinical testing that their version works equivalently, which costs far more and takes longer than bringing a generic tablet to market.
The Whole Drug Class Is Priced This Way
Ajovy competes with other injectable CGRP inhibitors like Aimovig, Emgality, and the IV-infused Vyepti. All of them target the same pain signaling pathway involved in migraines, and all carry similar annual price tags in the range of $7,000 to $10,000 per year. When every competitor is priced comparably, no company faces strong market incentive to drop their price significantly. The American Headache Society has noted this cost gap directly, comparing the roughly $10,000 annual cost of monthly Emgality injections against $1,400 for generic propranolol.
This pricing cluster exists partly because the drugs share similar manufacturing costs and development timelines, but also because insurers and pharmacy benefit managers negotiate behind the scenes through rebates. The list price you see isn’t necessarily what the insurer pays, but it is the starting point that determines your copay or out-of-pocket cost if you’re uninsured or underinsured.
Insurance Hurdles Add Friction
Most insurance plans require prior authorization before they’ll cover Ajovy. This means your doctor has to submit documentation proving you meet specific criteria. A typical plan requires that you’re an adult being treated for migraine prevention, and after the first three months, you’ll need to show a measurable reduction in monthly migraine days to continue coverage.
Some plans previously required step therapy, meaning you had to try and fail on cheaper preventive medications before Ajovy would be approved. That requirement has been loosened at some insurers. Johns Hopkins Health Plans, for example, removed their step therapy requirement for migraine prevention in 2024. But policies vary widely, and your plan may still require you to try older, less expensive options first.
Quantity limits also apply. Plans commonly authorize three autoinjectors every 75 days, matching the quarterly dosing option of 675 mg. If you and your doctor prefer monthly dosing, you may need separate authorization for that schedule.
What You Actually Pay Varies Widely
The $733 monthly list price is the wholesale acquisition cost, essentially the sticker price before any discounts. What you pay depends on your insurance, your plan’s formulary tier, and whether you use manufacturer assistance programs. Teva offers a copay savings card that can reduce costs for commercially insured patients, sometimes to as little as $0 to $5 per month. Without insurance or manufacturer help, you’re looking at close to full list price.
If you’re comparing Ajovy against older preventive options, the cost difference is real and significant. But the older drugs (beta-blockers, certain antidepressants, anti-seizure medications) work through different mechanisms, carry different side effect profiles, and don’t help everyone. For patients who haven’t responded to those options, the CGRP inhibitors represent a genuinely different approach to migraine biology, and that therapeutic value is part of what sustains the pricing across the entire class.